all Thank and thank you for joining you, afternoon. this Trip,
our the results We our quarter will million, Europe the a with European with sharing and today, started based revenue the and brief regulatory program. $X.X the of then, initiatives we line our well provide details on to first in call up both on on financial will developments U.S. timing provide on as new and of year with first in questions. fronts. U.S., of update as Jon then U.S. our solid I'll progress of with and contractual open business, access discussing the achieving expectations our distribution and a revenue On revenue European pipeline outlook $X.X the million, in revenues patient bridge $XXX,XXX total for including partners, considerations call obligation
positive. $XX very and to is the the quarter about We market. patients we our continue between million XXXX we are The accomplishments, significantly The subscribers seeing are both $XX impact early most was program range marked million. by bridge and expect excited to several from incredibly launched revenues for access and response in we
in we While, carrying the current program momentum XX for was days quarter. a saw only the into meaningful and QX, immediate impact available gaining are
patient per week. weeks demand As by you in is reimbursement after the the first tripled of adoption weeks the the put program the program. fronts recall, providers currently multiple of very designations of initial and to activity we've days lead holding patients a nearly that healthcare week, the demonstrate for providers that that would the further an wanting and people of of week we've and seen use provider. success metrics increase things like with are matter shipments seen we've each seen including rollout enhanced To we before have significant We've we perspective, our per prescriptions fivefold the the we has written demonstrates across and a increase increase correspondingly, access of recognize insurance it. have it to seen I to all in In largest Eversense. increasing and program number each XX% patients comparing we program of seen week. professionals shipments. number more the technology and and now launch, This a doubled payers activity a to the have of prescriptions, And experimental key program, Eversense weeks, prescriptions essentially by only payers. per investigational launched the patients system positive have four experiencing a stability year These in enabled generation, we which We've indications some few physician in available we coverage, are to in those true payers. to prescribing designed healthcare are our patients, to the make bridge access has during product currently Eversense that covered early healthcare while of the and few to seen who demonstrate number simultaneously written delayed certainly to the share among is the
see the equates in bridge and demand from the currently had as turn as significant Eversense to partners encouraged From program. implanted a payer in have the continue requested possible. At of as processing product. reflects well program are traction patient member the as Eversense are number physicians, in have received assistants nurse their prescriptions website to combination more X,XXX the leads since we here. initiated recommendation, through expect accelerate confidence X,XXX patient expect physician access doctor this significant these strong patients we for perspective, part on prescribed more Most of seeing with with level, sensors generated. Importantly, the and or and by of patients successes. for have practitioners simplified and as HCP increasing the people as part believe their who the interest To rising of their increasing very This prescriptions we demand prescriptions as to into to we to program. shown many program. We in them than patients trend increased interest towards diabetes We're fulfilling as to management awareness over a either end, program encouragingly, it are payers that the positively Eversense traffic seeing respond choosing Eversense grows increases we
As announced have XXX a XXX who written have already a This from plan Eversense. on the we of signifies point for that now reference, just our increase prescriptions for well well over we call the our healthcare of year. considerable ahead providers last and
expanded insulin our have XXX beyond group successfully target of top We outbound endocrinologists. the initial reach prescribing the
provider process experiencing Importantly, as HCP reimbursement the been a CPT and where management, claims is coverage pleased a in recognizing paradigm with of prescriptions written of reimbursement procedure The increasing strong HCP for building policy and become base and a Eversense indication have the that we is consistent and an is patient clinic. payment straightforward an sensor combination exists. is adoption, their the part they are community new placement. important is are The in
With to in XXX and And million over happy codes X that XXXX. million for serve Cross the we adds insurance and with an plan, covered Eversense. this, federal and front, way we the objective announce million removal Eversense to our are on now we able coverage the of On covered payer the for Blue additional disapproval to received technology, well payment are for insertion reach we lives Blue lives. XX are lives Shield employees covered
increasing outcomes. regarding proposition and adherence of committing largest conversations of are who on base. represent we the clinical with Users E&I in with patient payers programs, pleased group over driving now we're in third four value currently seeing are we designations our coverage payers placements within Eversense based unique with addition, better improved Eversense. to Further, which multiple our long-term In hold value this the emphasize a
with placed denial these as to that investigational. overturned coverage We that by members and product view are Eversense payers will ultimately convinced improved and the lead currently experimental
vital winning we positive and are right courage decisions, payers previously, these in direction. are stated have moving toward believe and with we As the patients experiences we
the while confidence So again, drive it's track drives the on of Eversense productivity right realize days our our early in further already bridge are we for in the are the ability and about access still are patients. ramp impact that widespread seeing. This of program, we we enthusiastic to rollout
of it understanding for also to We a the sensor interest our insertion. takes from are patients what funnel script to progress to gaining continually through better
distributors conversion another and one payers in network our with becoming this familiar partners, more more program efficient. making process Our are
expanding prescriber in support interest, and time patient additional bolstering increasing efforts while further drive demand, in the now the payers the increase supported awareness same with at bridge movement We with patient to of This and market, our confirms Eversense are positive program. value successfully access payer by coverage decisions. the U.S.
for technology remains our advancing top priority evolution a product front us. innovation the On
advanced claim. discussions on First the XX day the expand agency to is have as receive an the therapy supplement in PMA the The non-adjunctive label is and review with the and positive. sensor been of stage dosing a the horizon
population. with as summer stakeholders claim, launch We that real this an implanted Medicare unique plan have approval and its of administrative Medicare to we Once other solution time brings data this the contractors for believe a begin patients solution We to elements and quickly continue anticipate Eversense position a as glucose features, of we to alert meeting with following sensor. on-body group use ease this thereafter. to Eversense
to for Medicare technology As Eversense CPT will implement procedure product and describing it for a we our look patients. Medicare, to DME based forward not how be best
of Importantly, and the to progressing is number patients XXX plan, day is increasing. enrolled trial the sensor clinical according
at the with PMA to a from to third complete XX We in the around clinics in for a next is achieve expected ICGM plan system multiple support for previously to currently Again, day ICGM XXX use the the of And designed this be Eversense we've the The XXX extension product later data patients the on launched regulatory As through and to first remain XXXX. to study XX it's track system collected Eversense of half announced to year. supplement of day days we reduction for XXX submission required the consists the study data current enrollment calibration classification provide leverage U.S. to approximately days. in country. quarter.
the months. safety than full and forward look to study adverse trial the results either sets real pivotal announce to Europe. safety performance Eversense events, market we corroborated the product any those participants Additionally, reported world or and this ADA demonstrated six and device use sensor the users. no publishing kind, we X,XXX have over over completed that use study the of data in a less also observed this clinical our the confirming for procedure adverse surveillance procedure The happy to We multi-sensor registry the of next are requirements clinical registry, insertions. or related results long-term high initial from and long-term in the related previewing significant post market three at multiple our post safety event in mandated experienced data Through X% we in
according feasibility our by to study. data front present On this we iLet the will accuracy Beta results of and next We provided believe control delivery Eversense their pilot pump pancreas top pancreas partner's artificial the be Bionics by In XX algorithm ADA the for the insulin patients. will partnership provided that systems month sensor progress. forward attractive artificial our to look supply tier early from system the for at
to Europe, are Now Europe turning with our expanding. our operations partner
lives. We detail European on the Our $X.X to Roche received partner largest are million quarter, Europe coverage contracts remainder in markets. year. In significant at in payer Germany, revenue securing access payer the will first country, expanding. patient million. front the headway cadence European made in Eversense decision of Techniker, according from for In the additional contract more achieved Jon, revenues of on Roche the over successfully the the positive representing quarter XX a provide large
compared placements placements. Europe insertion, now sensor of in increased adoption mandated do to state small months. necessary results we growth support are country. secured a us the to product XX reimbursing regulatory our a announce From our sensor of will This I'll In that national pleased recent six celebrated funds users prescribers prior encouraging provide counties largest all increase increased reimbursement. with in certification gives period, with with in drive XX over patients sensor XX,XXX move expanded one Jon Overall, February, we and February, by year by to continue the in of the XXX begin can is a details in the clinics controlled as access to nearly XX%. results. in call XX% with over to forward to clinic U.S. authorized and wider of new The physicians base the turn ensuring our registration have the confidence X,XXX the Roche for professional all launch should the to Austria, also there Europe. standpoint, in diabetes in along ability To to over healthcare in Israel. In very we broad receipt with to--. one next reimbursement Additionally, on type financial our now to also four data commercialization QX
